Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide (VPCBAE) in the management of three patients with small-cell carcinoma of the ovary

John J Wallbillich; Alpa M Nick; Pedro T Ramirez; Jack L Watkins; Elizabeth D Euscher; Kathleen M Schmeler

doi:10.1016/j.gynor.2012.02.001

Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide (VPCBAE) in the management of three patients with small-cell carcinoma of the ovary

Gynecol Oncol Case Rep. 2012 Feb 13;2(2):58-60. doi: 10.1016/j.gynor.2012.02.001. eCollection 2012.

Authors

John J Wallbillich¹, Alpa M Nick², Pedro T Ramirez², Jack L Watkins³, Elizabeth D Euscher⁴, Kathleen M Schmeler²

Affiliations

¹ Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA.
² Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

► Ovarian small-cell carcinoma of the hypercalcemic type is a rare neoplasm with no standard treatment. ► The chemotherapy regimen including vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin and etoposide (VPCBAE) has limited toxicities and was effective in the 3 patients described in this case report.

Keywords: Chemotherapy; Ovarian cancer; Small cell.